Carmen BalaÃ±a

List of Publications by Year
in descending order

123	5,924	159585 30	79698 73
papers	citations	h-index	g-index

129	129	129	8224
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology, 2022, 24, 755-767.	1.2	25
2	Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics. Frontiers in Neurology, 2022, 13, .	2.4	13
3	RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMPâ€“negative Glioblastoma. Clinical Cancer Research, 2021, 27, 645-655.	7.0	5
4	Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns. Clinical and Translational Oncology, 2021, 23, 554-564.	2.4	14
5	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
6	Prospective pilot study to explore the melatonin level in brain tumor patients undergoing radiotherapy. Sleep and Breathing, 2021, , 1.	1.7	2
7	Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?. Neuro-Oncology, 2021, 23, 1616-1618.	1.2	0
8	The need for geriatric scales in glioblastoma. Aging, 2021, 13, 17959-17960.	3.1	0
9	Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT. Cancers, 2021, 13, 5420.	3.7	6
10	Hypoxia: The Cornerstone of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 12608.	4.1	62
11	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment. Cells, 2021, 10, 3529.	4.1	16
12	Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab. Clinical and Translational Oncology, 2020, 22, 411-419.	2.4	0
13	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. Clinical Cancer Research, 2020, 26, 6600-6609.	7.0	10
14	Reply to: â€œExtended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?â€• Neuro-Oncology, 2020, 22, 1889-1890.	1.2	2
15	Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Reports in Oncology, 2020, 13, 130-138.	0.7	4
16	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro-Oncology, 2020, 22, 1851-1861.	1.2	64
17	Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Scientific Reports, 2019, 9, 11125.	3.3	25
18	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica, 2019, 138, 1053-1074.	7.7	106

#	Article	IF	Citations
19	P14.58 Extending adjuvant temozolomide longer than six cycles doesnâ€™t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL. Neuro-Oncology, 2019, 21, iii80-iii80.	1.2	0
20	Prognostic value of stem cell markers in glioblastoma. Biomarkers, 2019, 24, 677-683.	1.9	5
21	Sub-Ventricular Zone Contact Influences Survival and Relapse Pattern in Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, E97.	0.8	0
22	Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS ONE, 2019, 14, e0217340.	2.5	18
23	A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma. Clinical and Translational Oncology, 2019, 21, 1364-1373.	2.4	7
24	ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITEÂ®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). Neuro-Oncology, 2019, 21, vi283-vi283.	1.2	14
25	Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma. Cancers, 2019, 11, 84.	3.7	4
26	Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.. Journal of Clinical Oncology, 2019, 37, 2001-2001.	1.6	6
27	Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a homogenously treated cohort: GLIOCAT project.. Journal of Clinical Oncology, 2019, 37, 2029-2029.	1.6	4
28	Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.. Journal of Clinical Oncology, 2019, 37, TPS2071-TPS2071.	1.6	9
29	Observational, multicenter, prospective study to assess the impact on patients' outcome of a systematic screening of oncogenic drivers in advanced cancer: The GETHI XX-16 study.. Journal of Clinical Oncology, 2019, 37, 3082-3082.	1.6	0
30	Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study. Journal of Neuro-Oncology, 2018, 137, 367-377.	2.9	8
31	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 2018, 94, 168-178.	2.8	28
32	SEOM clinical guidelines for anaplastic gliomas (2017). Clinical and Translational Oncology, 2018, 20, 16-21.	2.4	12
33	Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. Journal of Neuro-Oncology, 2018, 136, 363-371.	2.9	26
34	Dacomitinib: an investigational drug for the treatment of glioblastoma. Expert Opinion on Investigational Drugs, 2018, 27, 823-829.	4.1	17
35	Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy. Journal of Neuro-Oncology, 2018, 139, 779-780.	2.9	1
36	2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clinical and Translational Oncology, 2018, 20, 1361-1372.	2.4	35

#	Article	IF	Citations
37	Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clinical and Translational Oncology, 2018, 20, 1529-1537.	2.4	0
38	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumabâ€. Neuro-Oncology Practice, 2017, 4, 15-23.	1.6	6
39	Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines. Clinical and Translational Oncology, 2017, 19, 727-734.	2.4	7
40	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
41	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O⁶-Methylguanineâ€“DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology, 2017, 35, 343-351.	1.6	110
42	IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. Journal of Neuro-Oncology, 2017, 135, 273-284.	2.9	20
43	Evidence-based management of adult patients with diffuse glioma â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	10.7	5
44	Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Medicine, 2017, 6, 2858-2866.	2.8	44
45	Phase II trial of dacomitinib, a panâ€“human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-Oncology, 2017, 19, 1522-1531.	1.2	88
46	ECOG or Karnofsky Performance Status to Assess Functionality in Glioblastoma Patients Among Different Observers. Journal of Molecular Biomarkers & Diagnosis, 2017, 01, .	0.4	0
47	A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples. PLoS ONE, 2017, 12, e0170632.	2.5	100
48	Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. Anti-Cancer Drugs, 2016, 27, 133-137.	1.4	12
49	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. Journal of Clinical Oncology, 2016, 34, 2294-2302.	1.6	61
50	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532.	10.7	396
51	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 1386-1395.	10.7	357
52	Genotyping low-grade gliomas among Hispanics. Neuro-Oncology Practice, 2016, 3, 164-172.	1.6	4
53	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Journal of Neuro-Oncology, 2016, 127, 569-579.	2.9	40
54	Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS ONE, 2016, 11, e0161484.	2.5	12

#	Article	IF	Citations
55	2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. European Journal of Cancer, 2015, 51, S585.	2.8	1
56	A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clinical and Translational Oncology, 2015, 17, 743-750.	2.4	12
57	Economic Analysis Of Epicup, An Epigenetic Test To Predict The Tissue Of Origin In Cancer Of Unknown Primary Site, The Usa Payors Perspective. Value in Health, 2015, 18, A356.	0.3	5
58	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. Journal of Clinical Oncology, 2015, 33, 2015-2015.	1.6	25
59	Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site.. Journal of Clinical Oncology, 2015, 33, e12532-e12532.	1.6	1
60	IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain.. Journal of Clinical Oncology, 2015, 33, 2046-2046.	1.6	0
61	ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2014, 16, v81-v81.	1.2	4
62	A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. Anti-Cancer Drugs, 2014, 25, 717-722.	1.4	16
63	Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clinical and Translational Oncology, 2014, 16, 273-279.	2.4	13
64	Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study. Targeted Oncology, 2014, 9, 321-329.	3.6	34
65	Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. Journal of Neuro-Oncology, 2014, 116, 413-419.	2.9	34
66	Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. Journal of Neuro-Oncology, 2014, 117, 77-84.	2.9	20
67	Neoadjuvant Treatment Before Radiation for Patients With Glioblastoma (GBM) Only Biopsied: A Multicentric Phase 2 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2014, 90, S163-S164.	0.8	0
68	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, The, 2014, 15, e395-e403.	10.7	647
69	Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. Chinese Journal of Cancer, 2014, 33, 25-31.	4.9	25
70	Prognostic value of miR-196, IDO, and AXL in patients (p) with localized gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2014, 32, 10553-10553.	1.6	0
71	A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group.. Journal of Clinical Oncology, 2014, 32, 2028-2028.	1.6	0
72	Second primary malignances (SPMs) in patients with gastrointestinal stromal tumors (GIST): The potential influence of imatinib treatment.. Journal of Clinical Oncology, 2014, 32, 10552-10552.	1.6	0

#	Article	IF	Citations
73	Molecular profiling of low-grade gliomas (LGG) in Colombia (ONCOLGroup).. Journal of Clinical Oncology, 2014, 32, 2076-2076.	1.6	0
74	Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors. Clinical Sarcoma Research, 2013, 3, 3.	2.3	16
75	Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs, 2012, 23, 659-665.	1.4	37
76	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. European Journal of Cancer, 2012, 48, 3036-3044.	2.8	129
77	Comparison of 2 Consecutive Prospective Series of Unresectable High-grade Glioma Patients Treated With or Without Neoadjuvant (NA) Chemotherapy Before Standard Radiochemotherapy and Adjuvant Temozolomide. International Journal of Radiation Oncology Biology Physics, 2012, 84, S263.	0.8	0
78	Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. Journal of Neuro-Oncology, 2012, 109, 137-142.	2.9	38
79	SEOM guideline for the treatment of malignant glioma. Clinical and Translational Oncology, 2012, 14, 545-550.	2.4	5
80	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs, 2012, 30, 729-740.	2.6	36
81	Evolution of care for patients with relapsed glioblastoma. Expert Review of Anticancer Therapy, 2011, 11, 1719-1729.	2.4	6
82	Validation of the new graded prognostic assessment scale for brain metastases: a multicenter prospective study. Radiation Oncology, 2011, 6, 23.	2.7	51
83	Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?. Clinical and Translational Oncology, 2011, 13, 209-210.	2.4	14
84	Update on the diagnosis of cancer of unknown primary (CUP) origin. Clinical and Translational Oncology, 2011, 13, 434-441.	2.4	8
85	Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. Clinical and Translational Oncology, 2011, 13, 677-685.	2.4	34
86	A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.. Journal of Clinical Oncology, 2011, 29, 10072-10072.	1.6	5
87	Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009.. Journal of Clinical Oncology, 2011, 29, e12519-e12519.	1.6	1
88	Stem Cells in Brain Tumorigenesis and their Impact on Therapy. Current Stem Cell Research and Therapy, 2011, 6, 339-349.	1.3	1
89	Extended-schedule dose-dense temozolomide in refractory gliomas. Journal of Neuro-Oncology, 2010, 96, 417-422.	2.9	50
90	Phase II trial of temozolomide for leptomeningeal metastases: Safety and activity analysis.. Journal of Clinical Oncology, 2010, 28, e12528-e12528.	1.6	3

#	Article	IF	Citations
91	Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study.. Journal of Clinical Oncology, 2010, 28, 2074-2074.	1.6	0
92	Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. Journal of Clinical Oncology, 2009, 27, 1893-1898.	1.6	64
93	Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5) Tj ETQq1 1 0.784314 rgBT /Overlock Annals of Oncology, 2009, 20, 1794-1802.	1.2	63
94	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. European Journal of Cancer, Supplement, 2009, 7, 590.	2.2	2
95	Translational research in glioblastoma multiforme: molecular criteria for patient selection. Future Oncology, 2008, 4, 219-228.	2.4	16
96	Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT protein expression in a series of glioblastoma (GB) patients. Journal of Clinical Oncology, 2008, 26, 2037-2037.	1.6	1
97	Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety. Journal of Clinical Oncology, 2008, 26, 13011-13011.	1.6	1
98	MGMT promoter methylation status in newly diagnosed glioblastomas: Retrospective analysis from a clinical series of patients. Journal of Clinical Oncology, 2008, 26, 13021-13021.	1.6	0
99	Medulloblastoma in young adults. Must we give adjuvant chemotherapy?. Clinical and Translational Oncology, 2007, 9, 121-123.	2.4	3
100	Clinical course of high-grade glioma patients with a â€œbiopsy-onlyâ€•surgical approach: a need for individualised treatment. Clinical and Translational Oncology, 2007, 9, 797-803.	2.4	25
101	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. British Journal of Cancer, 2006, 94, 1797-1802.	6.4	2
102	A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecologic Oncology, 2006, 101, 545-547.	1.4	26
103	Clear Cell Adenocarcinoma Presenting as a Carcinoma of Unknown Primary Origin. , 2006, , 201-207.		0
104	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYXÂ®/DoxilÂ®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma, 2005, 9, 127-132.	1.3	27
105	Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo EspaÃ±ol de InvestigaciÃ³n en CÃ¡ncer de Ovario) study. Annals of Oncology, 2005, 16, 749-755.	1.2	106
106	CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas. Clinical Cancer Research, 2004, 10, 4933-4938.	7.0	523
107	Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). Journal of Neuro-Oncology, 2004, 70, 359-370.	2.9	32
108	Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas. Cancer, 2004, 100, 1498-1506.	4.1	18

#	Article	IF	Citations
109	Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): A potential positive selection bias-A study of the Spanish Group for Research on Sarcomas (GEIS). Journal of Surgical Oncology, 2004, 88, 44-49.	1.7	7
110	The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer, 2004, 46, 135-148.	2.0	34
111	Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS). Journal of Clinical Oncology, 2004, 22, 9033-9033.	1.6	1
112	A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Annals of Oncology, 2003, 14, 1425-1429.	1.2	23
113	O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clinical Cancer Research, 2003, 9, 1461-8.	7.0	111
114	Serum DNA as a tool for cancer patient management. , 2003, 48, 34-41.		16
115	Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer, 2002, 38, 309-315.	2.0	11
116	Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. Journal of Neuro-Oncology, 2002, 59, 81-90.	2.9	17
117	A combination of a fixed dose of carboplatin plus paclitaxel and adriamycin in first line therapy for advanced ovarian cancer and suboptimal surgical cytoreduction. A phase I trial of the Spanish group for ovarian cancer research and treatment (GEICO). European Journal of Cancer, 1999, 35, S239.	2.8	2
118	Title is missing!. Annals of Oncology, 1999, 10, 25-28.	1.2	5
119	Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. European Journal of Cancer, 1994, 30, 1043.	2.8	4
120	Etoposide (E) + epirebicin (E) + cisplatin (P) combination chemotherapy (EEP) In advanced gastric cancer: Negative impact on clinical outcome. Annals of Oncology, 1992, 3, 861-863.	1.2	19
121	A Prospective Randomized Trial of Continuous Infusion 5-Fluorouracil (5-FU) Versus 5-FU Plus Cisplatin in Patients with Advanced Colorectal Cancer A Trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). American Journal of Clinical Oncology: Cancer Clinical Trials, 1992, 15, 56-60.	1.3	14
122	Mitomycin-C and Vinblastine in Advanced Breast Cancer. Oncology, 1989, 46, 137-142.	1.9	15
123	Optimal duration of adjuvant temozolomide in glioblastoma: an unsolved and unsolvable problem. Neuro-Oncology Practice, 0, , .	1.6	0